Preámbulo 1
THE EUROPEAN COMMISSION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products ( 1 ) , and in particular the third subparagraph of Article 89(1) thereof,
Whereas:
HAS ADOPTED THIS REGULATION:
recital 1recital 1
(1) Commission Delegated Regulation (EU) No 1062/2014 ( 2 ) establishes a list of existing active substances to be evaluated for their possible approval for use in biocidal products. That list includes N-cyclopropyl-1,3,5-triazine-2,4,6-triamine (cyromazine).
recital 2recital 2
(2) Cyromazine has been evaluated for use in products of product-type 18, Insecticides, acaricides and products to control other arthropods, as described in Annex V to Regulation (EU) No 528/2012.
recital 3recital 3
(3) Greece was designated as evaluating competent authority and submitted the assessment reports together with its recommendations on 28 August 2014.
recital 4recital 4
(4) In accordance with Article 7(2) of Delegated Regulation (EU) No 1062/2014, the opinion of the European Chemicals Agency was formulated on 10 December 2015 by the Biocidal Products Committee, having regard to the conclusions of the evaluating competent authority.
recital 5recital 5
(5) According to that opinion, biocidal products of product-type 18 and containing cyromazine may be expected to satisfy the criteria of Article 19(1)(b) of Regulation (EU) No 528/2012, provided that certain specifications and conditions concerning their use are complied with.
recital 6recital 6
(6) It is therefore appropriate to approve cyromazine for use in biocidal products of product-type 18, subject to compliance with certain specifications and conditions.
recital 7recital 7
(7) Since cyromazine meets the criteria for being very persistent (vP) according to Annex XIII to Regulation (EC) No 1907/2006 of the European Parliament and of the Council ( 3 ) , treated articles treated with or incorporating cyromazine should be labelled appropriately when placed on the market.
recital 8recital 8
(8) A reasonable period should be allowed to elapse before an active substance is approved in order to permit interested parties to take the preparatory measures necessary to meet the new requirements.
recital 9recital 9
(9) The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Biocidal Products,
Artículo 1
N-cyclopropyl-1,3,5-triazine-2,4,6-triamine (cyromazine) is approved as an active substance for use in biocidal products of product-type 18, subject to the specifications and conditions set out in the Annex.
Artículo 2
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union .
Anexo 1ANNEX
Common Name IUPAC Name Identification Numbers Minimum degree of purity of the active substance ( 1 ) Date of approval Expiry date of approval Product type Specific conditions Cyromazine IUPAC Name: N-cyclopropyl-1,3,5-triazine-2,4,6-triamine EC No: 266-257-8 CAS No: 66215-27-8 950 g/kg 1 January 2018 31 December 2027 18 The authorisations of biocidal products are subject to the following conditions. (1) The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any use covered by an application for authorisation, but not addressed in the Union level risk assessment of the active substance. (2) In view of the risks identified for the uses assessed, the product assessment shall pay particular attention to: (a) professional users; (b) the surface water, sediment and soil compartment for products used in animal housing. (3) For products that may lead to residues in food or feed, the need to set new or to amend existing maximum residue levels (MRLs) in accordance with Regulation (EC) No 470/2009 of the European Parliament and of the Council ( 2 ) or Regulation (EC) No 396/2005 of the European Parliament and of the Council ( 3 ) shall be verified, and any appropriate risk mitigation measures shall be taken to ensure that the applicable MRLs are not exceeded. The placing on the market of treated articles is subject to the following condition: The person responsible for the placing on the market of a treated article treated with or incorporating cyromazine shall ensure that the label of that treated article provides the information listed in the second subparagraph of Article 58(3) of Regulation (EU) No 528/2012.